Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2009-016267-11 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This project may help to answer several fundamental questions related to public health regarding vaccination against influenza viruses and regarding the influenza A(H1N1)v pandemy:
What is the immunologic efficacy in terms of antibodies response of the vaccination against the seasonal (2009-2010) influenza virus and against the A(H1N1)v virus in the clinical staff?
Moreover, it may help to answer questions related to the use of a vaccine against influenza virus variants emerging in the French population:
Before the vaccination:
After the vaccination:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anti-H1N1v Vaccine | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anti-H1N1v Vaccine | Biological | Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the intensity of the humoral and cellular immune responses of the anti-A(H1N1)v vaccine in a medical care population as a function of the age and of the prior seasonal anti-influenza vaccinations. | 5 months |
| Measure | Description | Time Frame |
|---|---|---|
| Investigate the quality of the humoral and cellular immune responses induced by the seasonal anti-influenza vaccine as a function of the age and of the prior seasonal vaccinations. | 5 months | |
| Determine the cross-reactivity of the humoral and cellular immune responses as a function of the age and of the prior seasonal vaccinations |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stephane Jaureguiberry, MD | Groupe Hospitalier Pitie-Salpetriere | Principal Investigator |
| Behazine Combadiere, PhD | INSERM U945 | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hopital Pitie Salpetriere | Paris | Île-de-France Region | 75013 | France | ||
| Centre d'Investigations Cliniques (CIC), Hopital Cochin |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23776176 | Background | Bonduelle O, Yahia N, Siberil S, Benhabiles N, Carrat F, Krivine A, Rozenberg F, Dimitrov J, Kaveri SV, Curjol A, Tindel M, Louet M, Desert F, Launay O, Loulergue P, Badre G, Katlama C, Bricaire F, Samri A, Rousset D, van der Werf S, Jaureguiberry S, Combadiere B. Longitudinal and integrative biomodeling of effector and memory immune compartments after inactivated influenza vaccination. J Immunol. 2013 Jul 15;191(2):623-31. doi: 10.4049/jimmunol.1203483. Epub 2013 Jun 17. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 months |
| Assess the tolerance to the seasonal and pandemic vaccines | 5 months |
| Assess the occurence of flu episodes and their severity during the 2009-2010 season as a function of the age of the population. Then, the correlation between the flu episodes and and the immunologic results is to be evaluated. | 5 months |
| Evaluate the perception of the anti-influenza vaccination in a medical care population in the current H1N1v pandemy context. | 5 months |
| Paris |
| Île-de-France Region |
| 75014 |
| France |